Short-term transcutaneous electrical nerve stimulation reduces pain and improves the masticatory muscle activity in temporomandibular disorder patients: a randomized controlled trial by FERREIRA, Ana Paula de Lima et al.
112J Appl Oral Sci.
Abstract
Submitted: April 1, 2016
??????????????????????????
Accepted: August 14, 2016
Short-term transcutaneous electrical 
nerve stimulation reduces pain and 
improves the masticatory muscle 
activity in temporomandibular 
disorder patients: a randomized 
controlled trial
Studies to assess the effects of therapies on pain and masticatory 
muscle function are scarce. Objective: To investigate the short-term effect 
of transcutaneous electrical nerve stimulation (TENS) by examining pain 
intensity, pressure pain threshold (PPT) and electromyography (EMG) activity 
in patients with temporomandibular disorder (TMD). Material and Methods: 
Forty patients with myofascial TMD were enrolled in this randomized placebo-
controlled trial and were divided into two groups: active (n=20) and placebo 
(n=20) TENS. Outcome variables assessed at baseline (T0), immediately 
after (T2) and 48 hours after treatment (T1) were: pain intensity with 
the aid of a visual analogue scale (VAS); PPT of masticatory and cervical 
structures; EMG activity during mandibular rest position (MR), maximal 
voluntary contraction (MVC) and habitual chewing (HC). Two-way ANOVA 
????????????????????????????????????????????????????????????????????????
was set at 5%. Results: There was a decrease in the VAS values at T1 and 
T2 when compared with T0 values in the active TENS group (p<0.050). The 
??????????????????????????????????? ??????????? ??? ????????????????? ????
anterior temporalis and sternocleidomastoid (SCM) and T2 for the masseter 
?????????????????????????????????????????????????????????????????? ????????
and anterior temporalis was presented in the active TENS during MR at T1 
assessment when compared with T0 (p<0.050). The EMG activity of the 
??????????????????????????????????????????????????????????????????????????
at T1 and T2 when compared with placebo (p<0.050). The EMG activity 
??????????????????????????????????????????????????????????????????????????
the active TENS during HC at T1 when compared with placebo (p<0.050). 
Conclusions: The short-term therapeutic effects of TENS are superior to 
those of the placebo, because of reported facial pain, deep pain sensitivity 
and masticatory muscle EMG activity improvement.
Keywords: Temporomandibular joint disorders. Transcutaneous electric 
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Introduction
Transcutaneous Electrical Nerve Stimulation (TENS) 
has been used to control pain in patients with chronic 
temporomandibular disorders (TMD). However, the 
?????????????????????????????????????????????????????
muscles should be further investigated, considering 
that the evidence regarding the improvement of clinical 
parameters, e.g., reported pain, jaw movement and 
electromyography (EMG) activity, are divergent and 
controversial4,6,18,22.
It is well established that TENS can reduce patient-
reported pain intensity in acute pain conditions13, 
????????????????????????????????????????????????2,15. On 
the other hand, to the best of our knowledge, there 
is no published study on the effects of TENS on the 
pressure pain threshold (PPT) of masticatory muscles. 
????????????? ???????? ????? ???? ????????? ????????????
shown that TENS did not affect the PPT of upper 
trapezius trigger points11.
One study showed that the main effects of TENS 
on the muscular tonus of patients with TMD were: 1) 
reduction in muscle activity of the anterior portion 
of the anterior temporalis muscle, during resting 
posture of the jaw, and 2) increased muscle activity 
of the masseter muscles, during maximal voluntary 
contraction (clenching)22????????????????????????????
TENS as effective in reducing the EMG activity of the 
anterior temporalis and masseter muscles during 
resting posture of the jaw19.
Mandibular kinematics may be subjected to 
changes that may compromise the muscle and articular 
functions in TMD patients16. Therefore, in addition 
to pain assessment, identifying dysfunctional EMG 
behaviors will also be useful in providing therapeutic 
management and preventing the progression of 
signs and symptoms16. Furthermore, pain reduction 
and improved function are commonly the proposed 
goals for treating chronic musculoskeletal pain12. 
Nevertheless, pain and muscle function are often 
evaluated separately, and studies to assess the effects 
of therapies on pain and masticatory muscle function 
are scant in the literature.
Based on the above, the aim of this study was to 
investigate the short-term effect of TENS by examining 
pain intensity, PPT and EMG parameters in subjects with 
myofascial TMD. Our initial hypothesis was that TENS is 
as effective in reducing facial pain as it is in improving 
masticatory muscle EMG activity of TMD patients.
Material and Methods
Participants and design
Academic staff and undergraduate students of 
both genders from the Federal University of Sergipe 
were eligible. They underwent clinical evaluation for 
examination of signs and symptoms of TMD and, 
after the inclusion and exclusion criteria assessment, 
participants were divided into two groups: (1) TENS 
placebo (n=20) and (2) TENS active (n=20). The study 
design was a randomized placebo-controlled trial. 
One investigator (R1) who did not participate in data 
collection performed the randomization with the aid 
of computed-generated combinatorial analysis, which 
was used to generate the random sequence. A second 
investigator (R2) performed the eligibility assessment 
and the group allocation was made by sealed and 
opaque envelopes (concealed allocation). Operational 
issues precluded masking of the researcher who 
applied the treatment. Then, the same investigator 
(R2) who performed the group allocation also 
performed the treatment. A third investigator (R3), 
blinded for group allocation, conducted the outcome 
assessments. Finally, a fourth investigator (R4) carried 
out the interpretation and analysis of results. It is 
important to note that the participants of this study 
were also blinded regarding the type of treatment.
Sample size of at least 20 subjects per group was 
determined based on pilot evaluations, which would 
be suitable to detect a pressure pain threshold (PPT) 
difference of 1.02 kgf/cm2, standard deviation (SD) 
of 1.12 kgf/cm2???????????????????????????????????????
????????????????????????????????????
The Ethics Committee of the Federal University 
of Sergipe approved the study and the informed 
consent from each participant was obtained after full 
explanation of the research purposes and procedures.
Inclusion and exclusion criteria
The inclusion criteria was the diagnostic of chronic 
painful TMD (at least six months of pain complaint) 
according to the Research Diagnostic Criteria for 
Temporomandibular Disorders (RDC/TMD), categories 
Ia (myofascial pain without limited mouth opening) 
or Ib (myofascial pain with limited mouth opening)10. 
The exclusion criteria were: a) a history of facial or 
head trauma, rheumatic and orthopedic pathologies, 
surgical procedures performed in the craniocervical 
region and neurological diseases; b) diagnostic of other 
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chronic pain disorders, such as primary headaches, 
????????? ????? ?????????? ??? ????????????? ???? ??? ?????
contracptive; c) regular intake of medications, such 
as muscle relaxants, anticonvulsants, antidepressants 
and anxiolytics; d) any TMD treatment performed in 
the last three months; e) intake of any painkiller or 
oral contraceptive 24 h prior to the assessment. A 
detailed medical interview and clinical examination was 
carried out to evaluate inclusion and exclusion criteria. 
Also, the investigator responsible for the eligibility 
assessment (R2) was an orofacial pain specialist, 
trained and calibrated in the RDC/TMD examination 
technique.
Outcomes
Reported facial pain intensity and PPT (primary 
outcomes), as well as EMG activity (secondary 
outcome), were assessed.
Pain intensity
Visual analogue scale (VAS) was used to assess the 
intensity of current pain. VAS measures the painful 
experience using a straight line of 100 mm, with the 
left margin anchored by the term “no pain”, and the 
right, by the term “worst imaginable pain”3.
Pressure Pain Threshold (PPT)
PPT was conducted using an algometer (Kratos®, 
????????????????????????????????????????????????????????
surface of 1 cm2 coated with soft rubber. The patient 
was positioned comfortably in a sitting position, with 
muscles relaxed. The evaluator then placed the end 
of the circular surface of the algometer perpendicular 
to the skin and applied a steadily increasing pressure 
of 0.5 kg/cm2/second. The patient was instructed to 
verbalize the moment when the pressure exerted 
caused a painful sensation. The following sites were 
assessed: masseter muscles, anterior temporalis 
muscle, and sternocleidomastoid (SCM) and upper 
trapezius (bilaterally) muscles, in addition to the 
lateral pole of the jaw. The average of two trials was 
considered the PPT. There was a two-minute interval 
???????????????????????????????????????????? ????
????? ??????????????????????????????????????????????
the measurements of one muscle site and the other7.
Electromyography (EMG)
The surface EMG record was obtained using 
a Miotec®, model Miotool 400 4-channel system, 
which acquires the EMG signals (14-bit), with 
electrical isolation of 3,000 volts, high EMG signal 
representation across all channels (2000 samples/
second per channel), rejection of 110 dB common 
????? ???? ???? ?????? ????????? ???? ????????????????
Bit). The acquisition of EMG signals was performed 
using Miograph software with a 2000 Hz sampling 
???????????????????????????????????? ?????????????????
eliminated by the Notch Filter25. In performing the data 
analysis, the authors considered the amplitude of the 
electrical potential in microvolts (uV), expressed by 
the root mean square (RMS)1. Disposable and circular 
electrodes by Meditrace® were used, with a 20 mm 
distance between the poles. The ground electrode 
was placed in the lateral epicondyle of the left elbow 
of all volunteers.
A muscle function test performed before placing the 
electrodes served to identify the center of the muscles 
to be analyzed. The electrodes were placed parallel to 
???????????????????????????????????????????????????
the muscle origin and insertion. Before the exam 
itself, subjects were asked to perform a maximum 
?????????? ???????????? ??????? ?????????? ??? ?? ????
second isometric contraction of the masseter muscles 
and anterior temporalis muscle, in order to conduct 
normalization of the data, interpreted subsequently 
with the MATLAB.
EMG signal was captured in three tasks: in the 
mandibular rest position (MR), during MVC and during 
habitual chewing (HC). In measuring HC, Trident® gum 
was used for 20 chewing cycles1.
Assessments
All evaluations were made in three assessment 
times: baseline (T0), immediately after (T1) and 48 
hours after (T2) treatment. The participants were 
assessed according to the group allocation (intention-
to-treat analysis).
Treatment (Active TENS)
The volunteer was positioned in dorsal decubitus 
with knees supported on a triangular pillow placed 
between the volunteer’s chest and head. Electrodes 
were placed on both the masseter muscles and 
the anterior temporalis muscle beams, considering 
the same references that were used for electrode 
placement of the electromyography surface exam.
Before muscle stimulation, all participants were 
informed of the different types of interventions being 
FERREIRA APL, COSTA DRA, OLIVEIRA AIS, CARVALHO EAN, CONTI PCR, COSTA YM, BONJARDIM LR
2017;25(2):112-20
115J Appl Oral Sci.
tested in the research and of the perceived sensation 
of paresthesia from the electrodes, ranging from 
unnoticeable to hardly noticeable or very noticeable. 
The TENS device used was model Neurodyn Sapphire 
Compact Line, by Ibramed®, with two previously 
calibrated channels, and circular adhesive electrodes 
by Valutrode®, 3 cm in diameter. The parameters used 
in this study were: pulse duration only up to sensory 
activation (<100 us) and high intensities, but with 
an established limit to prevent muscle contraction 
and allow maximum comfort during the 50 minutes 
of therapy.
The total time of treatment was 50 min using 
variations of low and high frequency (VHF), with a 
?????? ??? ?? ??? ?????? ???????? ???? ??????? ?????? ???
min). This application protocol was based on previous 
evidence, which report different and complementary 
analgesic mechanism when adopting high and low 
frequencies9,20,24,26. The TENS device was connected 
to a placebo device with a selector key that was 
switched off, without the volunteers knowing this, in 
such a way not to allow them to distinguish between 
test procedure and placebo.
Treatment (placebo TENS)
Placebo device was developed in the Electrical 
Engineering Laboratory of the Federal University of 
Sergipe (GPRUFS), Robotics Research Group. The 
placebo equipment allowed the passage of current 
to the participant for only a short period of time (40 
seconds). The current was gradually reduced in such a 
way that the receiver would not be able to perceive the 
interruption in the stimulus. The placebo device had 
an internal resistance with values close to human body 
resistance. This system did not allow the electrical 
stimulation device to recognize that the current was 
not going through the individual, thus avoiding a false 
recording of non-contact electrodes.
Placebo procedure was performed with the placebo 
group positioned in the same way as the test group 
(active TENS), and with the same current parameters 
used for the test group. All the patients were told was 
that they were participating in a study involving the 
possibility of a placebo treatment.
Statistical analysis
Quantitative variables, i.e., age, body mass 
index – body mass divided by the square of the body 
height – (BMI), VAS, PPT and EMG at different tasks 
were presented as mean and standard deviation 
(SD). Variables were tested for data normality by 
the Kolmogorov-Smirnov test, and presented normal 
distribution (p>0.050).
The effect of TENS on VAS, PPT and EMG activity at 
different tasks (MR, MVC and HC) within and between 
the groups over time (before, immediately after and 
48 hours after application of TENS) was computed 
using two-way ANOVA for repeated measures followed 
by Tukey’s post??????????????????????? ??????????????
at 5%. In addition, the effect size of significant 
comparisons was computed according to Cohen’s 
????????????????????????????????????????????????????????
(d=0.20), moderate (d=0.50) and large (d=0.80) 




addition, Table 1 describes the general characteristics of 
????????????????? ??? ???????????????????????????????????
??????????????????????????????????????????????????
groups for gender, age and BMI (p<0.050). Moreover, 
no between-group difference was found in the VAS 
values at any assessment time (p>0.050). However, 
?????????????????????????????????????????????????????
T1 (d=-0.79) and T2 (d=-0.92) when compared with 
T0 values (within-group differences) only in the active 
TENS group (Figure 2).
PPT values of the anterior temporalis (d=1.13), 
?????????????????????????????????????????????????
higher in the active TENS and at T1 when compared 
with placebo, but also for the masseter (d=1.05) 
and SCM (d=1.38) at T2 (p<0.050) (Table 2). There 
????????????????????????????????????????????????????
of the assessment times considering the placebo 
?????? ??????????? ????????? ?????????? ?? ???????????
increase in the PPT values of masseter (d=0.57), 
anterior temporalis (d = 0.68), TMJ (d=1.10) and 
SCM (d=1.46) at T1 when compared with T0, and 
of masseter (d=0.46) at T2 compared with T1 in the 
active TENS group (p<0.050) (Table 2).
EMG activity of the masseter (T0, d=-2.57, T1, 
d=-4.58 and T2, d=-6.26) and anterior temporalis 
(T0, d =-2.03, T1, d=-3.69 and T2, d=-3.12) were 
????????????? ?????? ??? ?????????????????????????????
all assessment times when compared with placebo 
(p<0.050) (Table 3). Nevertheless, a significant 
EMG activity reduction of the masseter (d=-4.98) 
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and anterior temporalis (d=-3.77) was presented in 
the active TENS during MR at T1 assessment when 
compared with T0 (p<0.050), whereas the placebo 
increased MR EMG activity of the masseter (T0, d=0.37 
and T1, d=0.22) at T2 assessment when compared 
with T0 and T1 (p<0.050) (Table 3).
EMG activity of the anterior temporalis (T1, d=2.66 
??????????????????????????????????????????????????????







Gender - n(%) ns
Female 15 (75%) 15 (75%)
Male 5 (25%) 5 (25%)
Age (years) - Mean (SD) 24.15 (3.01)  25.10 (3.87) ns
BMI (Kg/m2) - Mean (SD 23.29 (2.28) 24.45 (5.80) ns
Axis I RDC/TMD - n(%)
IA   12(60%) 11(55%)
IA/IIA   7(35%) 8(40%)
IB 1 (5%) 0(0%)
IB/IIB 0 (0%) 1(5%)
???????????????????????????
RDC/TMD=Research Diagnostic Criteria for temporomandibular disorders.
IA=myofascial pain; IIA=disk displacement with reduction; IB= myofascial pain without
mouth opening limitation ;IIB=myofascial pain with mouth opening limitation
BMI= body mass index
Table 1- Baseline characteristics of the sample
Figure 1- ??????????????????????????????????????????????????????????????????
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increase in the EMG activity of the masseter (TENS 
active, d=2.05 and TENS placebo, d=1.12) and 
anterior temporalis (TENS active, d=1.42) was also 
observed in the active TENS and placebo during MVC 
at T1 when compared with T0 (p<0.050), whereas a 
?????????????????????????????????????????????????????????
temporalis (d=-1.71) in the placebo was observed 
during MVC at T1 when compared with (p<0.050) T0 
(Table 3).
EMG activity of the masseter (d=2.97) and anterior 
???????????????????? ?????? ??????????????????????????
the active TENS during HC at T1 when compared with 
????????????????????????????????????????????????????
increase in the EMG activity of the masseter (T1, 
d=3.11 and T2, d=0.95) and anterior temporalis (T1, 
d=3.32 and T2, d=1.33) was observed only in the 
active TENS during HC at T1 and T2 when compared 
with T0 (p<0.050) (Table 3).
Baseline (T0) Immediate (T1) 48 hours (T2)
Placebo TENS (n=20)
Masseter 1.69 (0.74)aA 1.62 (0.62)aA 1.71 (0.67)aA
Anterior Temporalis 1.83 (0.80)aA 2.02 (0.88)aA 2.09 (0.92)aA
TMJ 1.84 (0.31)aA 2.01 (0.47)aA 1.96 (0.41)aA
Sternocleidomastoid 1.32 (0.45)aA 1.46 (0.58)aA 1.49 (0.64)aA
Upper Trapezius 2.61 (0.85)aA 2.77 (0.94)aA 2.69 (1.09)aA
Active TENS (n=20)
Masseter 1.76 (0.59)aA 2.10 (0.59)bA 2.37 (0.58)cB
Anterior Temporalis 2.01 (0.69)aA 2.79 (0.38)bB 2.47 (0.41)cA
TMJ 1.97 (0.63)aA 2.56 (0.42)bB 2.30 (0.62)bA
Sternocleidomastoid 1.57 (0.57)aA 2.23 (0.28)bB 2.18 (0.30)bB
Upper Trapezius 2.93 (1.21)aA 3.43 (0.95)bA 2.70 (0.75)bA
????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
Table 2- Mean (SD) of the pressure pain threshold (PPT) values (Kgf/cm2) of masticatory muscles, temporomandibular joint (TMJ) and 
cervical muscles
VAS=visual analogue scale, T0=baseline, T1=immediately after treatment and T2=48 hours after treatment. Error-bars indicate the 
standard deviation of the mean
Figure 2- Mean of the pain intensity at all assessment times
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Discussion
This study demonstrated that mostly of TENS 
hypoalgesic properties and improvement in EMG 
activity in subjects with myofascial TMD are not 
??????????????????????????????????????????????????
term (T1 and T2) reduction in pain intensity; b) 
short-term increase in PPT values; (b) immediate (T1) 
reduction in MR EMG activity and short-term increase 
in MVC and HC EMG activity.
The evidence is controversial regarding the TENS 
effects of pain reduction in chronic pain disorders, 
though electrical nerve stimulation modalities in 
general are considered an effective treatment for 
chronic musculoskeletal pain. In particular, TENS 
seems to be effective on reducing pain in TMD patients. 
However, positive outcomes are generally not reported 
immediately after the application, but rather they are 
proposed as cumulative effects. Our study presented 
both, immediate (T1) and cumulative effects of TENS 
application (T2), which could be partially explained 
by the use of high frequency TENS. Previous evidence 
has reported immediate effects on TMD pain when 
applying only high frequency TENS. However, as far 
as we know, there is no published study comparing 
high and low frequency TENS in TMD patients, which 
warrants further researches.
A proper TMD evaluation would include muscle 
tenderness investigation, which can be done by manual 
palpation or with the aid of more standardized and 
reliable techniques, e.g., PPT assessment21. Previous 
evidence has shown inconsistent results of TENS effect 
on muscle tenderness in TMD patients, with reports 
of no effects on masseter and anterior temporalis 
pain upon palpation after four weeks14, but also with 
positive effects on pericranial muscle tenderness 
score (PTS) after 10 weeks8. Interestingly, this is 
????????????????????????????????????????????????????
of masticatory muscles, which reinforce the claimed 
positive effects of electrical therapy on muscle pain.
The pain adaptation model17 advocates that chronic 
muscle pain can reduce agonist muscle contraction 
and an increase antagonist muscle activity, in 
order to protect the agonist from new injuries19,23. 
???? ???????? ???? ???? ????????? ?????????? ?????? ????
increase at MVC and HC may point out TENS as an 
important contribution to lowering energy expenditure 
in maintaining jaw rest, and to improving the power 
Baseline (T0) Immediate (T1) 48 hours (T2)
Placebo TENS (n=20)
Mandibular rest
       Masseter 7.70 (1.52)aA 8.02 (1.44)aA 8.42 (1.11)bA
       Anterior Temporalis 8.51 (1.59)aA 8.82 (2.02)aA 8.65 (2.29)aA
Maximum Voluntary Contraction
        Masseter 160.66 (49.97)aA 217.20 (50.70)bA 190.65 (47.77)aA
        Anterior Temporalis 152.19 (52.70)aA 80.42 (26.60)bA 116.30 (39.64)bA
Habitual Chewing
       Masseter 19.94 (3.33)aA 23.14 (3.56)aA 23.99 (3.35)aA
       Anterior Temporalis 19.45 (2.58)aA 24.08 (6.00)aA 23.22 (5.28)aA
  Active TENS (n=20)
Mandibular rest
       Masseter 4.84 (0.40)aB 2.92 (0.37)bB 3.22 (0.38)bB
       Anterior Temporalis 5.78 (1.04)aB 2.89 (0.30)bB 3.53 (0.37)bB
Maximum Voluntary Contraction
      Masseter 134.64 (21.96)aA 205.82 (43.84)bA 179.13 (52.77)bA
      Anterior Temporalis 140.32 (19.44)aA 203.23 (59.49)bB 164.27 (45.83)aB
Habitual Chewing 
     Masseter 22.86 (2.41)aA 45.14 (9.82)bB 28.35 (7.78)cA
     Anterior Temporalis 20.36 (3.05)aA 44.10 (9.63)bB 27.16 (6.50)cA
???????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
Table 3- Mean (SD) of the electromyography values in microvolts expressed as Root Mean Square for the masseter and the anterior 
temporalis at different tasks
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?????????? ??? ???? ?????????? ??? ????????? ????? ?????
However, previous reports showed that high frequency 
????? ????? ???? ????????? ???? ????????? ????????????
and anterior temporalis muscles at clenching in 
TMD patients22. Discrepancy in the TENS application 
protocol could explain such differences, considering 
that variations in the stimulation frequency of TENS 
could be considered important to obtain unlikeness at 
MR or MVC22???????????????????????????????????????????????
???????????????????????????? ??????????? ????????????
of evaluation of muscle EMG activity at three different 
tasks, more researches are required to support our 
????????????????????????????????????????????
Such positive short-term effects of TENS on 
muscle pain and function could be related with the 
alternate frequencies protocol adopted in our study. 
This application protocol was based on previous 
evidence, which report different and complementary 
analgesic mechanism when adopting high and low 
frequencies9,26. High frequency TENS has been 
associated with segmental pain inhibition at neurons 
located in the dorsal horn and it can reduce nociceptive 
substances released in peripheral tissues24. In 
addition, low frequency TENS has been associated with 
??????????????????????????????????????????????? ????
descending pain modulation system24. Nevertheless, 
??????? ????????????????????????????????????????????????
the literature on the use of alternate frequencies in 
TMD patients. Considering that there is no sound 
conclusions regarding the optimal TENS protocol, 
further investigation is required not only to determine 
?????????????????????????????????????????????????????
for myofascial TMD but rather to establish guidelines 
for TENS application.
The strengths of this study are mainly related with 
the systematic assessment of myofascial TMD pain 
and muscle function using valid and reliable methods. 
On the other hand, some limitations that can be 
highlighted in this study were: a) lack of a long-term 
assessment; b) lack of a control group without any 
???????????????????????????????????????????????????????
and pain remission in TMD patients must be considered 
before any final judgment is made regarding 
??????????????????????????????????????? ??????????????
such procedure should be considered; c) lack of a 
control group without TMD, which could also elucidate 
the effects of TENS on asymptomatic muscles; d) risk 
of treatment bias, because the researcher who applied 
the treatment was aware about the group allocations.
Conclusions
Short-term therapeutic effects of TENS are superior 
to those of the placebo, because of the reported 
facial pain, deep pain sensitivity and masticatory 
muscle EMG activity improvement. Accordingly, we 
recommend the use of TENS as an effective option 
for short-term management of masticatory myofascial 
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